AIM: To evaluate prospectively 4 selected serum fibrosis markers (tenascin, hyaluronan, collagen VI, TIMP-1) before, during and 12 mo after IFN treatment of children with chronic hepatitis B. METHODS: Forty-seven consecutive patients with chronic hepatitis B (range 4-16 years, mean 8 years) underwent IFN treatment (3 MU tiw for 20 wk). Fibrosis stage and inflammation grade were assessed in a blinded fashion before and 12 mo after end of treatment. Serum fibrosis markers were determined using automated assays. RESULTS: IFN treatment improved histological inflammation but did not change fibrosis in the whole group or in subgroups. Only hyaluronan correlated significantly with histological fibrosis(r = 0.3383, P = 0.021). Basal fibrosis markers did not differ between responders (42.5%) and nonresponders(57.5%). During IFN treatment only serum tenascin decreased significantly in the whole group and in nonresponders. When pretreatment values were compared to values 12 mo after therapy, TIMP-1 increased in all patients and in nonresponders, and hyaluronan decreased in all patients and in responders. CONCLUSION: Tenascin reflects hepatic fibrogenesis and inflammation which decreases during IFN treatment of children with chronic hepatitis B. TIMP-1 correlates with nonresponse and hyaluronan with histological fibrosis.
AIM: To evaluate prospectively 4 selected serum fibrosis markers (tenascin, hyaluronan, collagen VI, TIMP-1) before, during and 12 mo after IFN treatment of children with chronic hepatitis B. METHODS: Forty-seven consecutive patients with chronic hepatitis B (range 4-16 years, mean 8 years) underwent IFN treatment (3 MU tiw for 20 wk). Fibrosis stage and inflammation grade were assessed in a blinded fashion before and 12 mo after end of treatment. Serum fibrosis markers were determined using automated assays. RESULTS:IFN treatment improved histological inflammation but did not change fibrosis in the whole group or in subgroups. Only hyaluronan correlated significantly with histological fibrosis(r = 0.3383, P = 0.021). Basal fibrosis markers did not differ between responders (42.5%) and nonresponders(57.5%). During IFN treatment only serum tenascin decreased significantly in the whole group and in nonresponders. When pretreatment values were compared to values 12 mo after therapy, TIMP-1 increased in all patients and in nonresponders, and hyaluronan decreased in all patients and in responders. CONCLUSION:Tenascin reflects hepatic fibrogenesis and inflammation which decreases during IFN treatment of children with chronic hepatitis B. TIMP-1 correlates with nonresponse and hyaluronan with histological fibrosis.
Authors: M L Shiffman; C M Hofmann; M J Contos; V A Luketic; A J Sanyal; R K Sterling; A Ferreira-Gonzalez; A S Mills; C Garret Journal: Gastroenterology Date: 1999-11 Impact factor: 22.682
Authors: F Bortolotti; P Jara; C Barbera; G V Gregorio; A Vegnente; L Zancan; L Hierro; C Crivellaro; G M Vergani; R Iorio; M Pace; P Con; A Gatta Journal: Gut Date: 2000-05 Impact factor: 23.059
Authors: Keyur Patel; Adrianne Lajoie; Shanon Heaton; Stephen Pianko; Cynthia A Behling; David Bylund; Paul J Pockros; Lawrence M Blatt; Andrew Conrad; John G McHutchison Journal: J Gastroenterol Hepatol Date: 2003-03 Impact factor: 4.029
Authors: Maria Elzbieta Sobaniec-Lotowska Sobaniec-Lotowska; Joanna Maria Lotowska; Dariusz Marek Lebensztejn Journal: World J Gastroenterol Date: 2007-06-07 Impact factor: 5.742
Authors: Pamela Valva; Paola Casciato; Juan M Diaz Carrasco; Adrian Gadano; Omar Galdame; María Cristina Galoppo; Eduardo Mullen; Elena De Matteo; María Victoria Preciado Journal: PLoS One Date: 2011-08-17 Impact factor: 3.240
Authors: Piotr Adrian Klimiuk; Izabela Domysławska; Stanisław Sierakowski; Justyna Chwiećko Journal: Rheumatol Int Date: 2014-09-05 Impact factor: 2.631